Apagliflozin and empagliflozin, both SGLT2 inhibitors, havedemonstrated a significant decrease in all-cause and cardiovascular mortality, aswell as in hospitalizations for HF and renal events in individuals with HF withreduced ejection fraction (HFrEF), independent of their diabetes status. This evidence concerns the gene SLC5A2 and hydrops fetalis.